Extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone

Bookmark and Share
Published: 5 Jun 2016
Views: 1543
Rating:
Save
Dr Paul Goss - Massachusetts General Hospital Cancer Center, Boston, USA

Dr Goss presents at ASCO 2016, a Randomised​ Phase III Open Label Trial which looked at extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.

Read the news story for more.